% | $
Quotes you view appear here for quick access.

OncoGenex Pharmaceuticals, Inc. Message Board

  • jd9919 jd9919 Feb 27, 2012 9:02 PM Flag

    Synergy with HSP90 inhibition

    Interesting (albeit preliminary) ...

    News Breaks
    February 27, 2012
    08:03 EDT OGXI OncoGenex reports positive data for compound OGX-427
    OncoGenex announced that preclinical data utilizing their pipeline compound OGX-427 was presented at the 27th Annual EAU Congress.This preclinical study, along with previously reported preclinical data, further demonstrated the potential of OGX-427 to augment anti-cancer therapies and delay tumor progression. The study showed that when Hsp27 was decreased via OGX-427 treatment, the effect of the Hsp90 inhibitors was enhanced and tumor cell death was observed. The authors concluded OGX-427 in combination with Hsp90 inhibitors potentiated the effects of Hsp90, delayed tumor growth and prolonged survival in murine prostate cancer models.

    Switching subjects, why-oh-why did I ever buy DNDN at $30???!!! (just venting)

0.90-0.02(-2.17%)Jul 22 3:59 PMEDT